New vaccine targets rare liver cancer's genetic flaw
NCT ID NCT06789198
First seen Feb 16, 2026 · Last updated Jun 02, 2026 · Updated 14 times
Summary
This early-stage trial tests a personalized peptide vaccine for people with a rare liver cancer called fibrolamellar hepatocellular carcinoma (FLC) or other tumors that share a specific genetic change (DNAJB1-PRKACA fusion). The vaccine is designed to train the body's immune cells to recognize and attack cancer cells carrying this fusion. The study will enroll about 20 participants who have achieved complete remission after standard treatments, to see if the vaccine is safe and triggers a strong immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Tuebingen
RECRUITINGTübingen, 72076, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitätsklinikum Tübingen, Kinderheilkunde I
NOT_YET_RECRUITINGTübingen, 72076, Germany
Contact Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.